Can-Fite BioPharma Ltd. (CANF): Cash & Equivalents
$5.53M
As of 2025-12-31
+22.9%
3-year compound annual growth
-7.7%
5-year compound annual growth
| Period ended | Cash & Equivalents | Change YoY | Source filing |
|---|---|---|---|
| 2025-12-31 | $5.53M | +14.6% | 2026-03-26, Balance as of period end |
| 2024-12-31 | $4.83M | +12.8% | 2026-03-26, Balance as of period end |
| 2023-12-31 | $4.28M | +43.7% | 2025-04-14, Balance as of period end |
| 2022-12-31 | $2.98M | -32.2% | 2024-03-28, Balance as of period end |
| 2021-12-31 | $4.39M | -46.9% | 2023-03-30, Balance as of period end |
| 2020-12-31 | $8.27M | +206.6% | 2022-03-24, Balance as of period end |
| 2019-12-31 | $2.70M | -25.4% | 2021-03-25, Balance as of period end |
| 2018-12-31 | $3.62M | n/a | 2021-03-25, Balance as of period end |
Cash & Equivalents at similar companies
| Company | Year ended | Cash & Equivalents | Change YoY |
|---|---|---|---|
| Can-Fite BioPharma Ltd. (CANF) | 2025-12-31 | $5.53M | +14.6% |
| Medicinova Inc (MNOV) | 2025-12-31 | $30.81M | -23.7% |
| Scienture Holdings, Inc. (SCNX) | 2025-12-31 | $6.66M | n/a |
| Provectus Biopharmaceuticals, Inc. (PVCT) | 2025-12-31 | $251.3K | -18.3% |
| Mereo BioPharma Group plc (MREO) | 2025-12-31 | $40.99M | -41.3% |
| Allarity Therapeutics, Inc. (ALLR) | 2025-12-31 | $14.69M | -24.8% |
| Vyome Holdings, Inc (HIND) | 2025-12-31 | $4.98M | n/m |
| Lipella Pharmaceuticals Inc. (LIPO) | 2024-12-31 | $2.18M | -33.7% |
| Abvc Biopharma, Inc. (ABVC) | 2025-12-31 | $681.5K | +174.4% |
Compare CANF, MNOV, SCNX, PVCT side by side · Screen every company in Pharmaceutical Preparations ↗